3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Head and Neck Neoplasms
2
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Pheochromocytoma
1
Ovarian Neoplasms
1
Optic Nerve Glioma
1
Oligodendroglioma
1
Neoplasms by Site
1
Neoplasms
1
Mesothelioma, Malignant
1
Medulloblastoma
1
Liver Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Gliosarcoma
1
Glioma, Subependymal
1
Glioma
1
Glioblastoma
1
Familial ependymoma
1
Ependymoma
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Medullary
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Breast Diseases
1
Brain Neoplasms
1
Interventions
Fulvestrant
2
Alpelisib
2
tipifarnib
1
ribociclib
1
palbociclib
1
exemestane
1
abemaciclib
1
Tamoxifen
1
STX-478
1
SF 1126
1
Panobinostat
1
PX-866
1
Metformin
1
Letrozole
1
Imlunestrant
1
Everolimus
1
Docetaxel
1
Cetuximab
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Tamoxifen
×
Head & Neck
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled